Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Status: Completed

Protocol number: BM18248

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A randomized, double-blind study to determine the effect of GK Activator (2) on efficacy (HbA1c), safety, tolerability and pharmacokinetics in patients with type 2 diabetes mellitus

Brief summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral GK Activator (2), compared to placebo, in patients with type 2 diabetes mellitus. The anticipated time on study treatment is less than 3 months, and the target sample size is 100-500 individuals. Target sample size is 250.

Study phase: II

Study type: Interventional; Treatment; Randomized; Double Blind; Active; Parallel; Safety/Efficacy study

Condition: Diabetes Mellitus, Type 2

Intervention type: Drug

Intervention name: GK Activator (2)

Primary outcome: 1. HbA1c mean change from baseline, compared to placebo. Time frame: Week 12

Key secondary outcomes: 1. Additional parameters of glycemic and lipid control. Time frame: Week 12 2. AEs, laboratory parameters. Time frame: Throughout study 3. Pharmacokinetic and exposure-response relationship Time frame: Throughout study

Inclusion criteria:

  • adult patients 30-75 years of age;
  • type 2 diabetes mellitus for >3 months before screening;
  • treatment-naive, inadequately controlled diabetes despite diet and exercise, or inadequately controlled diabetes in patients on monotherapy or combination therapy (maximum of 2 oral anti-hyperglycemic medications).

Exclusion criteria:

  • type 1 diabetes mellitus;
  • women who are pregnant, breast-feeding or not using adequate contraceptive methods.

Gender: Males or Females

Age limits: Min: 30 Years Max: 75 Years

Accepts healthy volunteers: No

Trial registration date: 12/09/2005

Date last updated: 8/19/2008


Link to trial result

This trial was conducted at the following locations:

Bulgaria

  • Dimitrovgrad
  • Pleven
  • Ruse
  • Sofia

Croatia

  • Zagreb

Guatemala

  • Guatemala City

Hungary

  • Budapest
  • Gyor
  • Kecskemet

Mexico

  • Chihuahua
  • Cuernavaca
  • Durango
  • Mexico City

Poland

  • Bialystok
  • Gdansk
  • Gorzow
  • Wroclaw

United States

  • Tucson , AZ
  • Chula Vista, CA
  • Spring Valley, CA
  • West Hills, CA
  • Hollywood, FL
  • Atlanta, GA
  • Binghamton, NY
  • Fayetteville, NC
  • Statesville, NC
  • Springdale, OH
  • Oklahoma City, OK
  • Medford, OR
  • Beaver, PA
  • Tipton, PA
  • Mount Pleasant, SC
  • Renton, WA

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply